Medicare AdvantagePrior AuthLow impact
Icotyde™ (icotrokinra) (New)
Humana·Dermatology, Rheumatology·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Icotyde™ (icotrokinra), a medication for moderate-to-severe plaque psoriasis in patients 12+ years old weighing at least 40kg. Requires trial or contraindication to two preferred medications before approval.
Action Required
By May 27, 2026: Billing team must update prior authorization procedures for Icotyde™ (icotrokinra) prescriptions for Medicare Advantage patients with plaque psoriasis. Ensure providers document patient age (12+ years), weight (40+ kg), diagnosis of moderate-to-severe plaque psoriasis, and trial/contraindication history for two preferred medications (Humira, Enbrel, Cosentyx, Skyrizi, Stelara/Otulfi/Yesintek, or Tremfya) before submitting prior auth requests.